Abstract Interleukin-6 (IL-6) is a pivotal cytokine with a diverse repertoire of physiological
functions that include regulation of immune cell proliferation and differentiation …

Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …

Several haematological malignancies, including multiple myeloma (MM) and acute myeloid
leukaemia (AML), have well-defined precursor states that precede the development of overt …

Signal transducer and activator of transcription 3 (STAT3), a member of the STAT protein
family, can be phosphorylated by receptor-associated Janus kinases (JAKs) in response to …

Multiple myeloma (MM) is a malignant plasma cell (PC) disorder, characterized by a
complex interactive network of tumour cells and the bone marrow (BM) stromal …

The number of novel therapies for the treatment of myeloma is rapidly increasing, as are the
clinical trials evaluating them in combination with other novel and established therapies …

Bone marrow is the primary hematopoietic organ, which is involved in multiple malignant
diseases including acute and chronic leukemia, multiple myeloma, myelodysplastic …

Our previous studies showed that macrophages (MФs), especially myeloma-associated MФs
(MAMs), induce chemoresistance in human myeloma. Here we explored the potential of …

Multiple myeloma (MM), which is characterized by osteolytic bone lesions, anemia,
hypercalcemia, and renal failure, accounts for approximately 10% of all hematologic …

Multiple myeloma develops primarily inside the bone marrow microenvironment, that confers
pro-survival signals and drug resistance. 3D cultures that reproduce multiple myeloma-bone …